HLA-G molecules are costitutively expressed by human synovial fibroblasts and up-modulated in osteoarthritis

Monica De Mattei¹, Roberta Rizzo², Marina Stignani², Agnese Pellati¹, Federica Masieri¹, Gaetano Caruso³, Angelo Caruso¹, Alessia Ongaro¹

¹ Department of Morphology and Embryology, University of Ferrara, Italy

² Department of Experimental and Diagnostic Medicine, Section of Medical Genetics, University of Ferrara, Italy

³ Department of Biomedical Sciences and Advanced Therapies, Orthopaedic Clinic, University of Ferrara, Italy

Objective HLA-G molecules are non classical HLA class I antigens expressed as membrane bound and soluble isoforms (sHLA-G) with a restricted tissue distribution and anti-inflammatory functions [1]. Osteoarthritis (OA) is a complex degenerative disease that affects articular cartilage components and causes damage to the entire joint structure including synovium [2]. Since inflammation is involved in the pathogenesis of OA, we have analyzed the expression and the production of HLA-G molecules in "in vitro" cultured synovial fibroblasts (SFs) from OA patients and control subjects.

Design We have analyzed the levels of sHLA-G1 and HLA-G5 isoforms by immunoenzymatic assay (ELISA) in the SFs culture supernatants from six OA patients and six control subjects during a 70 day "in vitro" cultures in the presence and in the absence of lipopolysaccharide (LPS) or recombinant IL-10 (rIL-10). We have confirmed HLA-G modulation by cytofluorimetry and immunofluorescence.

Results Data in ELISA have demonstrated the spontaneous production of sHLA-G molecules by both OA and control SFs. The expression has been confirmed by cyto-fluorimetry and immunofluorescence. OA SFs produce higher levels of sHLA-G1 and HLA-G5 molecules during the first 23 days of culture in comparison to control SFs. The sHLA-G1 levels further increase over the next 20 days of "in vitro" culture. Atfer LPS and rIL-10 treatments, sHLA-G secretion increases in a similar manner in both OA and control SFs.

Conclusions The production of sHLA-G1 molecules, constitutively expressed by control and OA SFs, is significantly higher in OA than in control SFs, suggesting that these molecules represent a possible molecular target to counteract the synovial joints inflammation.

References

[1] Baricordi OR et al. (2008) Inflamm Allergy Drug Targets. 7:67-74.

[2] Rousseau JC et al. (2007) Nat Clin Pract Rheumatol. 3:346-56.